Rebamipide kontra Diquafosol og Cyclosporine for perioperativt tørr øye ved kataraktkirurgi
Rebamipide kontra Diquafosol-Cyclosporin for perioperativ tørr øyesykdom ved kataraktkirurgi: En randomisert studie
The goal of this clinical trial is to compare the efficacy of 2% rebamipide monotherapy versus a combination therapy of 3% diquafosol and 0.05% cyclosporine for the management of dry eye disease in patients undergoing cataract surgery. It will also evaluate the safety and ocular surface stability effects of these treatments during the perioperative period.
The main questions it aims to answer are:
Does rebamipide monotherapy maintain tear film breakup time (TBUT) and prevent corneal damage as effectively as the combination therapy after surgery? How do patient symptoms (OSDI scores) and inflammation markers (MMP-9) change with each treatment?
Researchers will compare the rebamipide group to the diquafosol-cyclosporine combination group to evaluate their effects on perioperative dry eye management.
Participants will:
Use the assigned study eye drops starting 1 month before their cataract surgery and continuing for 3 months after surgery.
Visit the clinic for eye examinations at baseline, the day of surgery, and at 1 week, 1 month, and 3 months postoperatively.
Undergo tests including tear film breakup time measurement, corneal staining, Schirmer's test, and tear MMP-9 level assessments.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Dry eye disease (DED) is common in patients undergoing cataract surgery and may worsen during the perioperative period, leading to ocular discomfort and delayed visual recovery. Pharmacologic treatments targeting tear film instability and ocular surface inflammation are therefore important in perioperative management.
This prospective, randomized, parallel-group clinical trial compared two perioperative treatment strategies for DED in patients scheduled for cataract surgery. Eligible participants with pre-existing dry eye disease were randomized in a 1:1 ratio to receive either topical rebamipide 2% monotherapy or combination therapy with topical diquafosol 3% and cyclosporine 0.05%. Study medications were initiated 1 month prior to surgery and continued for 3 months postoperatively.
The primary outcome measure was the change in tear film breakup time (TBUT) during the early postoperative period. Secondary outcome measures included changes in corneal staining graded by the Oxford scale, patient-reported symptoms assessed by the Ocular Surface Disease Index (OSDI), tear secretion measured by Schirmer's test, and ocular surface inflammation evaluated using a tear matrix metalloproteinase-9 (MMP-9) point-of-care immunoassay.
Clinical assessments were performed at baseline, on the day of surgery, and at postoperative week 1, month 1, and month 3. Safety was evaluated by monitoring intraoperative and postoperative adverse events throughout the study period.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
Seoul
-
Seoul, Seoul, Sør -Korea
- Samsung Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Adults scheduled for cataract surgery
-
Presence of dry eye disease, defined as an Ocular Surface Disease Index (OSDI) score ≥12 and at least one of the following:
- Tear film breakup time (TBUT) ≤7 seconds
- Oxford corneal staining grade ≥1
- Schirmer's test value ≤10 mm/5 min
-
Ability and willingness to comply with the study protocol and follow-up schedule
-
Provision of written informed consent
Exclusion Criteria:
- Presence of ocular surface or ocular conditions that could affect dry eye status (e.g., active keratitis or ocular infection)
- Use of topical intraocular pressure-lowering medications
- History of ocular surgery other than cataract surgery in the study eye
- Any systemic or ocular condition judged by the investigator to interfere with study participation or outcome assessment
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Group R
Participants receive topical rebamipide 2% ophthalmic solution four times daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively. |
Topical administration, four times daily |
|
Aktiv komparator: Group DC
Participants receive topical diquafosol 3% ophthalmic solution four times daily in combination with cyclosporine 0.05% ophthalmic solution twice daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively. |
Topical administration, four times daily Topical administration, two times daily |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Tear Film Breakup Time (TBUT)
Tidsramme: From baseline to postoperative week 1
|
Change in tear film breakup time (TBUT) from baseline and during the early postoperative period following cataract surgery, comparing rebamipide monotherapy with diquafosol-cyclosporine combination therapy. |
From baseline to postoperative week 1
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Ocular Surface Disease Index (OSDI) Score
Tidsramme: From baseline to 1 and 3 months postoperatively
|
Change in patient-reported ocular symptoms assessed using the Ocular Surface Disease Index (OSDI) questionnaire, comparing rebamipide monotherapy with diquafosol-cyclosporine combination therapy. The OSDI score ranges from 0 to 100, with higher scores indicating more severe ocular surface symptoms (worse outcomes). |
From baseline to 1 and 3 months postoperatively
|
|
Change in Corneal Staining Grade (Oxford Scale)
Tidsramme: From baseline to postoperative week 1, and to 1 and 3 months postoperatively
|
Change in corneal epithelial staining graded using the Oxford grading scale (0-5) following fluorescein staining, comparing ocular surface staining severity between treatment groups. Higher grades indicate more severe corneal epithelial staining (worse outcomes). |
From baseline to postoperative week 1, and to 1 and 3 months postoperatively
|
|
Change in Schirmer's Test Value
Tidsramme: From baseline to 1 and 3 months postoperatively
|
Change in tear secretion measured by Schirmer's test without anesthesia, comparing tear production between rebamipide monotherapy and diquafosol-cyclosporine combination therapy. |
From baseline to 1 and 3 months postoperatively
|
|
Change in Tear Matrix Metalloproteinase-9 (MMP-9) Level
Tidsramme: From baseline to 1 and 3 months postoperatively
|
Change in tear matrix metalloproteinase-9 (MMP-9) levels assessed using a point-of-care immunoassay (InflammaDry), comparing ocular surface inflammation between treatment groups. |
From baseline to 1 and 3 months postoperatively
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Øyesykdommer
- Tåreapparatsykdommer
- Linsesykdommer
- Grå stær
- Syndromer med tørre øyne
- Farmasøytiske løsninger
- Peptider
- Aminosyrer, peptider og proteiner
- Farmasøytiske preparater
- Farmakologiske handlinger
- Kjemiske handlinger og bruk
- Terapeutisk bruk
- Polysykliske forbindelser
- Løsninger
- Spesialbruk av kjemikalier
- Makrosykliske forbindelser
- Peptider, syklisk
- Cyclosporins
- Syklosporin
- Oftalmiske løsninger
- rebamipide
- diquafosol
Andre studie-ID-numre
Andre studie-ID-numre
- SMC RVK Trial I
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The detailed study protocol and the data that support the findings of this study are available from the corresponding author upon reasonable request.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .